AbbVie places bet on Parvus’ Treg platform for IBD

2024-03-21

引进/卖出免疫疗法

AbbVie could add a new modality to its flagship immunology portfolio, thanks to a deal with Parvus Therapeutics announced Wednesday.

The pharma gained an exclusive, worldwide option to develop and commercialise inflammatory bowel disease (IBD) therapies developed with Parvus’ Treg immune tolerization platform technology.

The biotech’s therapeutics, dubbed Navacims, present multivalent peptide-MHCs to T-cells, which triggers their expansion and differentiation into antigen-specific Tregs to induce organ-specific immune tolerance without compromising normal immunity to infections and cancer.

The deal’s terms were not disclosed. In addition to an upfront payment, Parvus is eligible for a potential equity investment, as well as milestones and royalties.

Parvus also has an ongoing partnership with Roche’s Genentech unit to develop Navacim therapeutics for autoimmune diseases, which could pay out more than $800 million.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构